Affinity medicant conjugates

Abstract

In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

What is claimed is: 
     
       1. A compound comprising: an illudofulvene moiety selected from the group consisting of analogs  115 ,  121 ,  122 ,  127 ,  146 ,  255  and  289 . 
     
     
       2. A composition comprising the compound of  claim 1 , and a physiologically compatible excipient. 
     
     
       3. A composition comprising racemic mixtures of any enantiomers of the compound of  claim 1 . 
     
     
       4. A composition comprising the compound of  claim 1 , in the form of a liposomal particle, a nanoparticle, or a PEGylated compound. 
     
     
       5. A composition comprising the compound of  claim 1 , and a physiologically compatible carrier.